-

SHAREHOLDER ALERT: Robbins LLP Announces That 3D Systems Corp. (DDD) is Being Sued for Misleading Shareholders

SAN DIEGO & ROCK HILL, S.C.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of 3D Systems Corp. (NYSE: DDD) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between May 6, 2020 and March 1, 2021. 3D Systems provides comprehensive 3D printing and digital manufacturing services and digital design tools.

If you suffered a loss due to 3D Systems Corp.'s misconduct, click here.

3D Systems Corp. (DDD) Lacked Proper Internal Controls Over Financial Reporting

According to the complaint, throughout the class period, 3D Systems attested to the accuracy of its financial reporting and disclosure controls and procedures.

On March 1, 2021, 3D Systems issued a press release announcing a delay in filing their 10-K annual report for the fiscal year ended December 31, 2020. Specifically, "the delay in filing is primarily related to the presentation of cash flows associated with the divestiture process for its Cimatron and GibbsCam software business." Further, "the company discovered certain internal control deficiencies. As a result, the company will report material weaknesses in internal controls in its fiscal 2020 Annual Report on Form 10-K." On March 2, 2021, 3D Systems filed a NT-10-K with the SEC, stating that their 10-K filing would be delayed for the reasons stated in their March 1 release. On this news, 3D Systems stock price fell $7.62 per share, or almost 20%, to close at $31.17 per share on March 2, 2021.

If you purchased shares of 3D Systems Corp. (DDD) between May 6, 2020 and March 1, 2021, you have until June 8, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against 3D Systems Corp. Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related i...
Back to Newsroom